ArticleMolecular oncology2008
Trends in the global funding and activity of cancer research.
Article in Molecular oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Critical appraisal of translational research models for suitability in performance assessment of cancer centers.The oncologist · 2012Pooled it
- Bibliometric analysis of focal therapy in prostate cancer research.BJUI compass · 2024Article
- Mapping the European cancer prevention research landscape: A case for more prevention research funding.European journal of cancer (Oxford, England : 1990) · 2023Article
- General practice-based cancer research publications: a bibliometric analysis 2013-2019.The British journal of general practice : the journal of the Royal College of General Practitioners · 2023Observational
- The status of bladder cancer research worldwide, a bibliometric review and recommendations.Arab journal of urology · 2023Article
- Cancer Survivorship in the Indo-Pacific: Priorities for Progress.JCO global oncology · 2023Review
- Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers.Current oncology (Toronto, Ont.) · 2022Article
- Barriers and Facilitators to Conducting Oncology Clinical Trials in the UAE.Clinics and practice · 2022Review
- Towards Better Pharmaceutical Provision in Europe-Who Decides the Future?Healthcare (Basel, Switzerland) · 2022Article
- Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective.Asia-Pacific journal of clinical oncology · 2022Article
- Does conflict of interest affect the reported fusion rates of bone graft substitutes and extenders?North American Spine Society journal · 2022Review
- Defining research and infrastructure priorities for cancer survivorship in Australia: a modified Delphi study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine.European urology open science · 2021Article
- Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials.Current oncology (Toronto, Ont.) · 2021Article
- Patient-Derived Xenograft vs. Organoids: A Preliminary Analysis of Cancer Research Output, Funding and Human Health Impact in 2014-2019.Animals : an open access journal from MDPI · 2020Article
- Epigenetic therapy of novel tumour suppressor ZAR1 and its cancer biomarker function.Clinical epigenetics · 2019Article
- Mapping the Global Cancer Research Funding Landscape.JNCI cancer spectrum · 2019Article
- Landscape of Global Oncology Research and Training at National Cancer Institute-Designated Cancer Centers: Results of the 2018 to 2019 Global Oncology Survey.Journal of global oncology · 2019Article
- The impact of the open-access status on journal indices: oncology journals.Journal of gastrointestinal oncology · 2019Article
- Mission-oriented translational cancer research - health economics.Molecular oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer research has carved an astonishing trajectory giving rise to a multi billion euro global network covering most domains of science and including all manner of research funders from industry to government and philanthropic funders. We have estimated that in 2004/2005 the global spend on cancer research was 14,030 million euro, with the USA, dominated by the NCI (c. 83%) accounting for the largest absolute spend. This is between 2 and 3 times the level of per capita spend compared to EU-15 and Europe, respectively. In Europe, the UK is at comparable levels of spend compared to the USA. Funding for cancer research in Europe is split almost 50:50 between philanthropic and governmental sources. Cancer research productivity in terms of outputs (publications) is slightly greater in Europe compared to the USA with an increasing trend towards more applied (clinical) outputs. Both the USA and Europe have equally strong industry-supported output levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.